SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Valley Radiology Consultants On October 1, 2026, we acquired substantially all of the assets of VRC Holdings, LLC and Valley Radiology Consultants Medical Group, Inc. (collectively, “Valley Radiology Consultants”) for total purchase consideration of approximately $7.0 million. Valley Radiology Consultants operates three imaging centers located in Southern California. University Diagnostic Medical Imaging On October 1, 2026, we acquired substantially all of the assets of URMA LLC and University Diagnostic Medical Imaging, P.C. (collectively, “UDMI”) for total purchase consideration of approximately $10.0 million. UDMI operates one imaging center located in the Bronx, New York. Imagen Technologies, Inc. On October 8, 2026, we acquired 11.4 million shares of Series E preferred stock of Imagen Technologies, Inc. (“Imagen”) for approximately $35.0 million. In connection with the investment, we entered into commercial agreements for the provision and distribution of DeepHealth software solutions and a data partnership agreement granting Imagen access to certain imaging data for artificial intelligence development and commercialization. Under the data partnership agreement, we received a warrant to purchase up to 7.2 million shares of Imagen common stock at an exercise price of $0.01 per share, which vests based on the volume of imaging studies requested, provided and accepted. ONRAD, Inc. On October 26, 2026, we entered into a definitive agreement to acquire ONRAD, Inc. ("ONRAD"), a provider of teleradiology and in-hospital radiology staffing services. Under the terms of the agreement, we will pay $350.0 million in cash, subject to customary adjustments, and issue 5.0 million shares of our common stock at closing. The agreement also provides for additional contingent consideration of up to $210.0 million based on ONRAD's achievement of a specified adjusted EBITDA target for the year ending December 31, 2027, payable in cash, shares of our common stock, or a combination thereof. The transaction is subject to customary regulatory approvals and closing conditions and is expected to close during the first quarter of 2027.

On October 1, 2026, we acquired substantially all of the assets of VRC Holdings, LLC and Valley Radiology Consultants Medical Group, Inc. (collectively, “Valley Radiology Consultants”) for total purchase consideration of approximately $7.0 million. Valley Radiology Consultants operates three imaging centers located in Southern California.

On October 1, 2026, we acquired substantially all of the assets of URMA LLC and University Diagnostic Medical Imaging, P.C. (collectively, “UDMI”) for total purchase consideration of approximately $10.0 million. UDMI operates one imaging center located in the Bronx, New York.

On October 8, 2026, we acquired 11.4 million shares of Series E preferred stock of Imagen Technologies, Inc. (“Imagen”) for approximately $35.0 million. In connection with the investment, we entered into commercial agreements for the provision and distribution of DeepHealth software solutions and a data partnership agreement granting Imagen access to certain imaging data for artificial intelligence development and commercialization. Under the data partnership agreement, we received a warrant to purchase up to 7.2 million shares of Imagen common stock at an exercise price of $0.01 per share, which vests based on the volume of imaging studies requested, provided and accepted.

On October 26, 2026, we entered into a definitive agreement to acquire ONRAD, Inc. ("ONRAD"), a provider of teleradiology and in-hospital radiology staffing services. Under the terms of the agreement, we will pay $350.0 million in cash, subject to customary adjustments, and issue 5.0 million shares of our common stock at closing. The agreement also provides for additional contingent consideration of up to $210.0 million based on ONRAD's achievement of a specified adjusted EBITDA target for the year ending December 31, 2027, payable in cash, shares of our common stock, or a combination thereof. The transaction is subject to customary regulatory approvals and closing conditions and is expected to close during the first quarter of 2027.